Skip to main content
JNJJohnson & JohnsonSell5.5·$225.33
JNJ · Decision

Should you buy Johnson & Johnson (JNJ)?

Updated

JNJ shows quality-resilience (V7 bonus +0.2, Q=7.1) with wide moat and BREAKOUT setup (golden cross, RSI 68), but V9 ASYMMETRY:-0.4=NEGATIVE and V8 'Target reached (-2.3% upside)' plus weak growth (2.5) trigger NO_EDGE and AVOID — maintain only.

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Verdict
SELL
Score
5.5/10
Price
$225.33
Entry / Take Profit (TP) / Stop Loss (SL)
/ $227.66 / $216.97

Engine methodology range

Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.

What the engine is tracking

Quality subscore of 7.1 with ROE 26%, margins 22%, wide economic moat (moat=7.6), and 'Compounder quality' note earns the V7 quality-resilience bonus of +0.2 in RISK_OFF regimes.

stable
Bull case (item 1)
Expectation
Quality subscore stays >= 7.0 and moat component holds above 7.0 across 4 quarters.

CounterQuality.notes flags 'Rule of 40: 23 (fail)' and 'Earnings quality warning: 59% FCF/NI' — quality may be cosmetic above the surface.

Sector modifier (Healthcare): +0.5 (bull_case[1]) provides a structural defensive premium during RISK_OFF regimes.

stable
Bull case (item 2)
Expectation
Healthcare sector modifier stays positive (>= +0.3) across the next 4 refreshes.

CounterSector tailwinds are regime-dependent; a shift to RISK_ON could flip the modifier negative as capital rotates to growth.

V9 setup_type=BREAKOUT with rationale 'Golden cross, above all MAs, RSI 68, MACD bullish' plus momentum subscore 7.1 and rising OBV (volume accumulation) confirm institutional buying.

stable
Setup type
Expectation
Momentum subscore stays >= 6.5 with OBV component holding at 10/10 for 2 quarters.

CounterRSI 68 is approaching overbought; bollinger component at 0.0 suggests price is stretched and a mean-reversion pullback is likely.

▸ Show 2 more pillars (SSR-indexed, visually truncated)

Bear_case flags 'Weak growth' with growth subscore 2.5, earnings_growth component 0.0/10, and PEG 3.05 — the engine cannot find a growth path.

stable
Bear case (item 2)
Expectation
Growth subscore must climb above 4.5 with earnings_growth component above 4.0 over 4 quarters to remove this headwind.

CounterDefensive compounders rarely score well on growth; the score may permanently underweight JNJ's stable revenue base.

V9 ASYMMETRY:-0.4=NEGATIVE with current_price $233 above take_profit $229.47, V8 explicitly flags 'Target reached (-2.3% upside)' — no reward setup remains at spot.

stable
Engine gate (failed)
Expectation
Analyst take_profit advances above $255 (~10% above spot) to restore asymmetry_ratio above 1.0.

CounterAnalyst targets often re-rate upward after sustained breakouts; technicals are bullish and TP may catch up.

→ Full pillar scorecard with all 5 pillars + per-dimension breakdown

When this thesis breaks

Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Quality subscore of 7.1 with ROE 26%, margins 22%, wide economic moat (moat=7.6), and 'Compounder quality' note earns the V7 quality-resilience bonus of +0.2 in RISK_OFF regimes.

    Trip ifQuality subscore falls below 6.0 or moat component drops below 6.0.

  • P2Sector modifier (Healthcare): +0.5 (bull_case[1]) provides a structural defensive premium during RISK_OFF regimes.

    Trip ifHealthcare sector modifier falls below 0 on the next refresh.

  • P3V9 setup_type=BREAKOUT with rationale 'Golden cross, above all MAs, RSI 68, MACD bullish' plus momentum subscore 7.1 and rising OBV (volume accumulation) confirm institutional buying.

    Trip ifPrice closes below 200-day MA or MACD component drops below 5.0.

  • P4Bear_case flags 'Weak growth' with growth subscore 2.5, earnings_growth component 0.0/10, and PEG 3.05 — the engine cannot find a growth path.

    Trip ifGrowth subscore stays below 3.0 for 2 consecutive refreshes.

  • P5V9 ASYMMETRY:-0.4=NEGATIVE with current_price $233 above take_profit $229.47, V8 explicitly flags 'Target reached (-2.3% upside)' — no reward setup remains at spot.

    Trip ifV9 asymmetry_ratio stays below 0 for 3 consecutive refreshes.

How the engine reached this verdict

1. Direct answer

TrendMatrix's engine output for Johnson & Johnson (JNJ) is SELL_IF_HOLDING with medium conviction, score 5.5/10 at $225.33. The F-path SELL output reflects an overall score of 5.4 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 0.21 is supplementary context, not the trigger.

2. Entry, target, and stop

The engine's exit framework anchors to a tactical sell band near $225.33, with structural invalidation at $216.97. The asymmetric R:R against a reversal hypothesis is 0.27 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).

3. What the engine sees

On the bull side: High-quality business; Wide economic moat. On the bear side: Analyst target reached - limited upside remaining; Weak growth. Active engine warnings: V8: Target reached (1.0% upside), V9 Gate Failed: ASYMMETRY:0.2<1.5@spot.

4. What would change the verdict

The dominant failed gate is reward-to-risk at 0.2 vs threshold 1.5. SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:5.8>=5.5.

For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates JNJ — 10-dimension breakdown →

Bull case

  • High-quality business
  • Wide economic moat

Bear case

  • Analyst target reached - limited upside remaining
  • Weak growth
Home Stocks JNJ Buy or sell?